Thomas Gardner, Michael Koch, Arieh Shalhav, Richard Bihrle, Richard Foster, Christopher Steidle, Ivan Grunberger, Alan Seftel, Martin Resnick, James Cochran, Victor Rao, Narendra Sanghvi
Phase III multicenter study was conducted in the USA under the FDA approved protocol, to establish the safety and efficacy of High Intensity Focused Ultrasound (HIFU) in the treatment of Benign Prostatic Hyperplasia (BPH) using the Sonablate? system. A total of sixty eight patients have been treated to date in the Phase III study. Transrectal probes capable of real-time ultrasound imaging of the prostate and well as delivering the HIFU energy to the selected region in the prostate gland were used. Probes with different focal lengths were used to treat different size of prostate glands. The patients were treated in one treatment session and were followed up to a period of one year following the treatment. The subjects underwent physical exam, Digital Rectal Examination (DRE), cystoscopy, Transrectal Ultrasound (TRUS), blood work, urine exam and were given standard questionnaires before treatment and during the follow up period. Under this protocol HIFU was found to be safe and effective in reducing the BPH related symptoms and improving the peak urinary flow rate with preservation of sexual function and no permanent side effects.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.